NZ519381A - New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders - Google Patents
New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disordersInfo
- Publication number
- NZ519381A NZ519381A NZ519381A NZ51938100A NZ519381A NZ 519381 A NZ519381 A NZ 519381A NZ 519381 A NZ519381 A NZ 519381A NZ 51938100 A NZ51938100 A NZ 51938100A NZ 519381 A NZ519381 A NZ 519381A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antipsychotic
- indol
- methyl
- dioxino
- tetrahydro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45860799A | 1999-12-10 | 1999-12-10 | |
PCT/US2000/033060 WO2001041750A2 (en) | 1999-12-10 | 2000-12-07 | Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ519381A true NZ519381A (en) | 2004-04-30 |
Family
ID=23821437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ519381A NZ519381A (en) | 1999-12-10 | 2000-12-07 | New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1235570A2 (ru) |
JP (1) | JP5557409B2 (ru) |
KR (1) | KR100772854B1 (ru) |
CN (1) | CN1230164C (ru) |
AR (1) | AR026756A1 (ru) |
AU (1) | AU784211B2 (ru) |
BR (1) | BR0016168A (ru) |
CA (1) | CA2396351C (ru) |
CZ (1) | CZ20021880A3 (ru) |
EA (1) | EA005002B1 (ru) |
HK (1) | HK1045942A1 (ru) |
HU (1) | HUP0203309A3 (ru) |
IL (2) | IL149669A0 (ru) |
MX (1) | MXPA02005649A (ru) |
NO (1) | NO20022739D0 (ru) |
NZ (1) | NZ519381A (ru) |
PL (1) | PL355292A1 (ru) |
TW (1) | TWI222864B (ru) |
WO (1) | WO2001041750A2 (ru) |
ZA (1) | ZA200205484B (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06004752A (es) | 2003-10-29 | 2006-07-05 | Wyeth Corp | Composiciones farmaceuticas de liberacion mantenida que contienen aplindore y sus derivados. |
AR052674A1 (es) | 2005-02-17 | 2007-03-28 | Wyeth Corp | Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados |
PL2254598T3 (pl) * | 2008-02-13 | 2013-12-31 | Targacept Inc | Połączenie agonistów receptorów nikotynowych alfa 7 i środków przeciwpsychotycznych |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2987484B2 (ja) * | 1995-03-16 | 1999-12-06 | 大塚製薬 株式会社 | カルボスチリル誘導体の製造方法 |
US5756532A (en) * | 1995-11-06 | 1998-05-26 | American Home Products Corporation | Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives |
GB9627005D0 (en) * | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
-
2000
- 2000-12-07 WO PCT/US2000/033060 patent/WO2001041750A2/en active IP Right Grant
- 2000-12-07 JP JP2001543095A patent/JP5557409B2/ja not_active Expired - Lifetime
- 2000-12-07 AR ARP000106504A patent/AR026756A1/es unknown
- 2000-12-07 CN CNB008169527A patent/CN1230164C/zh not_active Expired - Lifetime
- 2000-12-07 EP EP00982461A patent/EP1235570A2/en not_active Withdrawn
- 2000-12-07 BR BR0016168-3A patent/BR0016168A/pt not_active Application Discontinuation
- 2000-12-07 EA EA200200656A patent/EA005002B1/ru not_active IP Right Cessation
- 2000-12-07 IL IL14966900A patent/IL149669A0/xx active IP Right Grant
- 2000-12-07 AU AU19490/01A patent/AU784211B2/en not_active Ceased
- 2000-12-07 NZ NZ519381A patent/NZ519381A/en unknown
- 2000-12-07 CZ CZ20021880A patent/CZ20021880A3/cs unknown
- 2000-12-07 HU HU0203309A patent/HUP0203309A3/hu unknown
- 2000-12-07 CA CA002396351A patent/CA2396351C/en not_active Expired - Lifetime
- 2000-12-07 MX MXPA02005649A patent/MXPA02005649A/es active IP Right Grant
- 2000-12-07 KR KR1020027007286A patent/KR100772854B1/ko not_active IP Right Cessation
- 2000-12-07 PL PL00355292A patent/PL355292A1/xx not_active Application Discontinuation
- 2000-12-08 TW TW089126071A patent/TWI222864B/zh not_active IP Right Cessation
-
2002
- 2002-05-15 IL IL149669A patent/IL149669A/en not_active IP Right Cessation
- 2002-06-07 NO NO20022739A patent/NO20022739D0/no not_active Application Discontinuation
- 2002-07-09 ZA ZA200205484A patent/ZA200205484B/xx unknown
- 2002-10-09 HK HK02107378.5A patent/HK1045942A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR100772854B1 (ko) | 2007-11-02 |
CA2396351A1 (en) | 2001-06-14 |
AU784211B2 (en) | 2006-02-23 |
CA2396351C (en) | 2009-11-10 |
HK1045942A1 (zh) | 2002-12-20 |
CN1230164C (zh) | 2005-12-07 |
MXPA02005649A (es) | 2004-09-10 |
CN1409633A (zh) | 2003-04-09 |
EA200200656A1 (ru) | 2002-12-26 |
IL149669A0 (en) | 2002-11-10 |
JP2003516350A (ja) | 2003-05-13 |
WO2001041750A2 (en) | 2001-06-14 |
EA005002B1 (ru) | 2004-10-28 |
KR20030016207A (ko) | 2003-02-26 |
HUP0203309A2 (hu) | 2003-01-28 |
NO20022739L (no) | 2002-06-07 |
AU1949001A (en) | 2001-06-18 |
EP1235570A2 (en) | 2002-09-04 |
BR0016168A (pt) | 2002-08-20 |
AR026756A1 (es) | 2003-02-26 |
WO2001041750A3 (en) | 2002-02-14 |
IL149669A (en) | 2006-06-11 |
HUP0203309A3 (en) | 2004-12-28 |
ZA200205484B (en) | 2003-12-31 |
TWI222864B (en) | 2004-11-01 |
CZ20021880A3 (cs) | 2002-08-14 |
NO20022739D0 (no) | 2002-06-07 |
PL355292A1 (en) | 2004-04-05 |
JP5557409B2 (ja) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1994932A1 (en) | Use of N-desmethylclozapine to treat human psychosis | |
MX2007011436A (es) | Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas. | |
US20090258084A1 (en) | Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia | |
AU780817B2 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone | |
US20070238725A1 (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
US20090306040A1 (en) | Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia | |
US6350773B1 (en) | Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders | |
CA2649590A1 (en) | Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome | |
CA2396351C (en) | New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders | |
AU2004246820B2 (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
Cheng et al. | Dopamine hypothesis | |
MXPA05013580A (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |